Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy

Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy

BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN...

Full description

Bibliographic Details
Main Authors: Eric M Yoshida, Morris Sherman, Vincent G Bain, Curtis L Cooper, Marc Deschênes, Paul J Marotta, Samuel S Lee, Mel Krajden, Helga Witt-Sullivan, Robert J Bailey, Christopher Usaty, Kevork Peltekian, the Canadian Pegasys Study Group
Format: Article
Language:English
Published: Hindawi Limited 2009-01-01
Series:Canadian Journal of Gastroenterology
Online Access:http://dx.doi.org/10.1155/2009/470532
id doaj-2555567b69fc42b6807edfc1730ef787
record_format Article
spelling doaj-2555567b69fc42b6807edfc1730ef7872020-11-24T22:38:47ZengHindawi LimitedCanadian Journal of Gastroenterology0835-79002009-01-0123318018410.1155/2009/470532Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based TherapyEric M Yoshida0Morris Sherman1Vincent G Bain2Curtis L Cooper3Marc Deschênes4Paul J Marotta5Samuel S Lee6Mel Krajden7Helga Witt-Sullivan8Robert J Bailey9Christopher Usaty10Kevork Peltekian11the Canadian Pegasys Study GroupDivision of Gastroenterology, University of British Columbia, Vancouver, British Columbia, CanadaUniversity Health Network, Toronto, Ontario, CanadaUniversity of Alberta, Edmonton, Alberta, CanadaUniversity of Ottawa, Ottawa, Ontario, CanadaRoyal Victoria Hospital, Montreal, Quebec, CanadaUniversity of Western Ontario, London, Ontario, CanadaUniversity of Calgary, Calgary, Alberta, CanadaBC Centre for Disease Control, Vancouver, British Columbia, CanadaMcMaster University, Hamilton, Ontario, CanadaRoyal Alexandra Hospital, Edmonton, Alberta, CanadaRoche, Mississauga, Ontario, CanadaDalhousie University, Halifax, Nova Scotia, CanadaBACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported.http://dx.doi.org/10.1155/2009/470532
collection DOAJ
language English
format Article
sources DOAJ
author Eric M Yoshida
Morris Sherman
Vincent G Bain
Curtis L Cooper
Marc Deschênes
Paul J Marotta
Samuel S Lee
Mel Krajden
Helga Witt-Sullivan
Robert J Bailey
Christopher Usaty
Kevork Peltekian
the Canadian Pegasys Study Group
spellingShingle Eric M Yoshida
Morris Sherman
Vincent G Bain
Curtis L Cooper
Marc Deschênes
Paul J Marotta
Samuel S Lee
Mel Krajden
Helga Witt-Sullivan
Robert J Bailey
Christopher Usaty
Kevork Peltekian
the Canadian Pegasys Study Group
Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
Canadian Journal of Gastroenterology
author_facet Eric M Yoshida
Morris Sherman
Vincent G Bain
Curtis L Cooper
Marc Deschênes
Paul J Marotta
Samuel S Lee
Mel Krajden
Helga Witt-Sullivan
Robert J Bailey
Christopher Usaty
Kevork Peltekian
the Canadian Pegasys Study Group
author_sort Eric M Yoshida
title Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
title_short Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
title_full Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
title_fullStr Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
title_full_unstemmed Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
title_sort retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy
publisher Hindawi Limited
series Canadian Journal of Gastroenterology
issn 0835-7900
publishDate 2009-01-01
description BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported.
url http://dx.doi.org/10.1155/2009/470532
work_keys_str_mv AT ericmyoshida retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT morrissherman retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT vincentgbain retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT curtislcooper retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT marcdeschenes retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT pauljmarotta retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT samuelslee retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT melkrajden retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT helgawittsullivan retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT robertjbailey retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT christopherusaty retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT kevorkpeltekian retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
AT thecanadianpegasysstudygroup retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy
_version_ 1725711931698839552

Similar Items